Skip to main content
Erschienen in: Tumor Biology 5/2010

01.10.2010 | Research Article

Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women

verfasst von: Emanuela Anastasi, Teresa Granato, Giulia Giovanna Marchei, Valentina Viggiani, Barbara Colaprisca, Sara Comploj, Maria Gabriella Reale, Luigi Frati, Cecilia Midulla

Erschienen in: Tumor Biology | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

The objective of the present study was to investigate in healthy young women the fluctuations in serum concentration of human epididymal secretory protein human epididymis-specific protein 4 (HE4) and CA125 during the phases of the menstrual cycle and the correlation between HE4 and CA125 values and age. Forty women with regular menstrual cycles were included in the study. Pelvic and transvaginal ultrasound were performed in order to exclude ovarian pathologies. Blood samples were collected at follicular (FP), ovulatory (OP), and luteal (LP) phases of the hormonal cycle. The values of HE4 (expressed as picomoles per liter) observed were (mean ± SEM) 39.1 ± 1.1 (FP), 45.3 ± 1.19 (OP), and 42.0 ± 1.3 (LP). The difference between FP and OP was statistically significant (p = 0.0002). By contrast, serum CA125 levels (expressed as units per milliliter) were 14.35 ± 0.66 (FP), 13.15 ± 0.54 (OP), and 13.70 ± 0.54 (LP), respectively. The levels of HE4 observed in serum samples of women below 35 years were 37.5 ± 1.28 in the FP, 46.6 ± 1.4 in the OP, and 42.8 ± 1.49 in the LP. In this group, a statistically significant difference was observed in the FP compared with the OP (p < 0.0001), whereas no statistically significant difference was observed during the different hormonal phases in the group of women over 35. In conclusion, the correct interpretation of laboratory data is essential to define a threshold of normality, and for what concerns HE4 levels, the menstrual cycle phase-dependent variability appears indicated in the interpretation of the results.
Literatur
1.
Zurück zum Zitat Mallett S, Timmer A, Sauerbrei W, Altaman DG. Reporting of prognostic studies of tumor markers: a review of articles in relation to REMARK guidelines. Br J Cancer. 2010;102:173–80.CrossRefPubMed Mallett S, Timmer A, Sauerbrei W, Altaman DG. Reporting of prognostic studies of tumor markers: a review of articles in relation to REMARK guidelines. Br J Cancer. 2010;102:173–80.CrossRefPubMed
2.
Zurück zum Zitat Meany DL, Sokoll LJ, Chan DW. Early detection of cancer: immunoassay for plasma tumor markers. Expert Opin Med Diagn. 2009;3:597–605.CrossRefPubMed Meany DL, Sokoll LJ, Chan DW. Early detection of cancer: immunoassay for plasma tumor markers. Expert Opin Med Diagn. 2009;3:597–605.CrossRefPubMed
3.
Zurück zum Zitat Glassman RH, Ratain MJ. Biomarkers in early cancer drug development: limited utility. Pharmacol Ther. 2009;85:134–5.CrossRef Glassman RH, Ratain MJ. Biomarkers in early cancer drug development: limited utility. Pharmacol Ther. 2009;85:134–5.CrossRef
4.
Zurück zum Zitat Simon R. Clinical trial for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Per Med. 2010;7:33–47.CrossRefPubMed Simon R. Clinical trial for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Per Med. 2010;7:33–47.CrossRefPubMed
5.
Zurück zum Zitat Bon GS, Kenemans P, Dekker JJ, Hompes PG, Verstraeten RA, van Kamp GJ, et al. Fluctuations in CA125 and Ca15-3 serum concentrations during spontaneous ovulatory cycles. Hum Reprod. 1999;14:566–70.CrossRefPubMed Bon GS, Kenemans P, Dekker JJ, Hompes PG, Verstraeten RA, van Kamp GJ, et al. Fluctuations in CA125 and Ca15-3 serum concentrations during spontaneous ovulatory cycles. Hum Reprod. 1999;14:566–70.CrossRefPubMed
6.
Zurück zum Zitat Kafali H, Artunc H, Herdem M. Evaluation of factors that may be responsible for cyclic change of CA125 levels during menstrual cycle. Arch Gynecol Obstet. 2007;275:175–7.CrossRefPubMed Kafali H, Artunc H, Herdem M. Evaluation of factors that may be responsible for cyclic change of CA125 levels during menstrual cycle. Arch Gynecol Obstet. 2007;275:175–7.CrossRefPubMed
7.
8.
Zurück zum Zitat Bingle L, Singleton V, Bingle CD. The putative ovarian tumor marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein is forms. Ontogeny. 2002;21:2768–73. Bingle L, Singleton V, Bingle CD. The putative ovarian tumor marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein is forms. Ontogeny. 2002;21:2768–73.
9.
Zurück zum Zitat Claus A, Lila H, Lund wall A. The evolution of a genetic locus encoding small serine proteins inhibitors. Brioche Biophysics Res Common. 2005;333:383–9.CrossRef Claus A, Lila H, Lund wall A. The evolution of a genetic locus encoding small serine proteins inhibitors. Brioche Biophysics Res Common. 2005;333:383–9.CrossRef
10.
Zurück zum Zitat Claus A, Lila H, Lund wall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acid protein. Brioche J. 2002;368:233–42. Claus A, Lila H, Lund wall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acid protein. Brioche J. 2002;368:233–42.
11.
Zurück zum Zitat Hellerstrom I, Hellertown KE. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv Exp Med Biol. 2008;622:15–21.CrossRef Hellerstrom I, Hellertown KE. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv Exp Med Biol. 2008;622:15–21.CrossRef
12.
Zurück zum Zitat Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumor Biol. 2010;31:113–9.CrossRef Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumor Biol. 2010;31:113–9.CrossRef
13.
Zurück zum Zitat Chen DX, Schwartz PE, Li XG, Yang Z. Evaluation of CA125 levels in differentiating malignant from benign tumors in patients with pelvic mass. Obstet Gynecol. 1988;72:23–7.PubMed Chen DX, Schwartz PE, Li XG, Yang Z. Evaluation of CA125 levels in differentiating malignant from benign tumors in patients with pelvic mass. Obstet Gynecol. 1988;72:23–7.PubMed
14.
Zurück zum Zitat Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accuracy of CA125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol. 2009;142:99–105.PubMed Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accuracy of CA125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol. 2009;142:99–105.PubMed
15.
Zurück zum Zitat Tian C, Markman M, Zaino R, Ozols RF, McGuire WP, Muggia FM, et al. CA125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study. Cancer. 2009;115:1395–403.CrossRefPubMed Tian C, Markman M, Zaino R, Ozols RF, McGuire WP, Muggia FM, et al. CA125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study. Cancer. 2009;115:1395–403.CrossRefPubMed
16.
Zurück zum Zitat Urban N, McIntosh AM, Karlan B. Ovarian cancer screening. Hematol Oncol Clin North Am. 2003;17:989–1005.CrossRefPubMed Urban N, McIntosh AM, Karlan B. Ovarian cancer screening. Hematol Oncol Clin North Am. 2003;17:989–1005.CrossRefPubMed
17.
Zurück zum Zitat Ozols RF. Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol. 2002;20:1161–3.PubMed Ozols RF. Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol. 2002;20:1161–3.PubMed
18.
Zurück zum Zitat Boffetta P. Biomarkers in cancer epidemiology an integrative approach. Carcinogenesis. 2009;31:121–6.CrossRefPubMed Boffetta P. Biomarkers in cancer epidemiology an integrative approach. Carcinogenesis. 2009;31:121–6.CrossRefPubMed
19.
Zurück zum Zitat Riley RD, Saurbrei W, Altman DG. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis and beyond. Br J Cancer. 2009;100:1219–29.CrossRefPubMed Riley RD, Saurbrei W, Altman DG. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis and beyond. Br J Cancer. 2009;100:1219–29.CrossRefPubMed
20.
Zurück zum Zitat Planchard D, Loriot Y, Goubar A, Commo SJC. Differential expression of biomarkers in men and women. Semin Oncol. 2009;36:553–65.CrossRefPubMed Planchard D, Loriot Y, Goubar A, Commo SJC. Differential expression of biomarkers in men and women. Semin Oncol. 2009;36:553–65.CrossRefPubMed
21.
Zurück zum Zitat Kafali H, Artuc H, Demir N. Use of CA125 fluctuation during the menstrual cycle as a tool in the clinical diagnosis of endometriosis; a preliminary study. Eur J Obstet Gynecol Reprod Bio. 2004;116:85–8.CrossRef Kafali H, Artuc H, Demir N. Use of CA125 fluctuation during the menstrual cycle as a tool in the clinical diagnosis of endometriosis; a preliminary study. Eur J Obstet Gynecol Reprod Bio. 2004;116:85–8.CrossRef
22.
Zurück zum Zitat Erbagci AB, Ylmaz N, Kutlar I. Menstrual cycle dependent variability for serum tumor markers CEA, AFP, CA 19-9, CA125 and CA15-3 in healthy women. Dis Markers. 1999;15:259–67.PubMed Erbagci AB, Ylmaz N, Kutlar I. Menstrual cycle dependent variability for serum tumor markers CEA, AFP, CA 19-9, CA125 and CA15-3 in healthy women. Dis Markers. 1999;15:259–67.PubMed
23.
Zurück zum Zitat Zweers A, de Boever J, Serreyn R, Vandekerckhove D. Correlation between peripheral CA125 and ovarian activity. Fertil Steril. 1990;54:490–4. Zweers A, de Boever J, Serreyn R, Vandekerckhove D. Correlation between peripheral CA125 and ovarian activity. Fertil Steril. 1990;54:490–4.
24.
Zurück zum Zitat Kafali H, Artunc H, Erdem M. Evaluation of factors that may be responsible for cyclic change of CA125 levels during menstrual cycle. Arch Gynecol Obstet. 2007;275:175–7.CrossRefPubMed Kafali H, Artunc H, Erdem M. Evaluation of factors that may be responsible for cyclic change of CA125 levels during menstrual cycle. Arch Gynecol Obstet. 2007;275:175–7.CrossRefPubMed
25.
Zurück zum Zitat Creaney J, Robinson BW. Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med. 2009;15:366–70.CrossRefPubMed Creaney J, Robinson BW. Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med. 2009;15:366–70.CrossRefPubMed
26.
Zurück zum Zitat Zeimet AG, Muller-Holzner E, Marth C, Daxenbichler G, Dapunt O. Tumor marker CA125 in tissues of the female reproductive tract and in serum during the normal menstrual cycle. Fertil Steril. 1993;59:1028–35.PubMed Zeimet AG, Muller-Holzner E, Marth C, Daxenbichler G, Dapunt O. Tumor marker CA125 in tissues of the female reproductive tract and in serum during the normal menstrual cycle. Fertil Steril. 1993;59:1028–35.PubMed
Metadaten
Titel
Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women
verfasst von
Emanuela Anastasi
Teresa Granato
Giulia Giovanna Marchei
Valentina Viggiani
Barbara Colaprisca
Sara Comploj
Maria Gabriella Reale
Luigi Frati
Cecilia Midulla
Publikationsdatum
01.10.2010
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 5/2010
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-010-0049-1

Weitere Artikel der Ausgabe 5/2010

Tumor Biology 5/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.